Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: COVID-19
Interventions: AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Inflammation, Skin Inflammation, Aging
Interventions: CeraVe Moisturizing Cream, Vaseline; Other · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 70 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza
Interventions: Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Auburn, Maine

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions: Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity; Drug · Procedure · Behavioral
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Danicamtiv; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: palbociclib capsule: phase 1 and 2 studies, Palbociclib capsule: phase 3 studies, Palbociclib capsule: ICH; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed, Cohort 2: Lubiprostone Sprinkle Formulation, Fasted; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Macular Degeneration
Interventions: Omega-3 fatty acid; Dietary Supplement
Lead sponsor: Wills Eye; Other
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more

Conditions: Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions: ASP015K ER, ASP015K IR; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions: DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only); Biological
Lead sponsor: Nuravax, Inc.; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Rheumatoid Arthritis
Interventions: MR prednisone, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 28
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more

Conditions: Epithelial Ovarian Cancer
Interventions: Cvac, Placebo; Biological
Lead sponsor: Prima BioMed Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin, Perflubutane Microbubble, Contrast-Enhanced Ultrasound, Quality-of-Life Assessment, Computed Tomography, Magnetic Resonance Imaging; Drug · Other · Procedure
Lead sponsor: Flemming Forsberg; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: Ixabepilone; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Detroit, Michigan

Conditions: Shigella, Diarrhea
Interventions: IVT Shigella-04, Placebo (0.9% saline); Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Lice Infestations
Interventions: MALG, Ovide (malathion) lotion 0.05%, Permethrin 1%; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Scottsdale, Arizona • Miami, Florida • St. Petersburg, Florida + 3 more

Conditions: Healthy Participants
Interventions: Etrumadenant; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Neovascular Age-related Macular Degeneration
Interventions: SAR402663, Diluent; Biological · Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 19 more

Conditions: Asthma, Bronchiectasis
Interventions: DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra); Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Iron Overload Due to Transfusion-dependant Anemias
Interventions: Deferasirox dispersible tablet, Defearisox film-coated tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg; Drug
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Search by objective public record fields.

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Skin Barrier Function and Inflammation in Aging: The BIA Study

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Ixabepilone Administered as an Enteric Coated Formulation.

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study